和元生物：2025年全年净亏损19,500万元—23,700万元

Core Viewpoint - The company, Heyuan Bio, has announced a projected net loss for the fiscal year 2025, estimating a loss between 237 million yuan and 195 million yuan, although this represents a narrowing of losses compared to the previous year [1] Group 1: Business Impact - The domestic biopharmaceutical sector is experiencing a complex landscape of opportunities and challenges, characterized by diversified development and intense market competition [1] - The company is focusing on its core business in cell and gene therapy CRO/CDMO, leveraging national and industry development policies to strategically position itself in the regenerative medicine application field [1] - During the reporting period, all business segments of the company saw varying degrees of revenue growth, with a recovery in the cell and gene therapy industry expected in the second half of 2025 [1] Group 2: Operational Strategy - The company is prioritizing the enhancement of customer resource reserves, brand influence, and industry development, aiming to improve operational management capabilities and reduce costs [1] - Despite the planned advancement of the CDMO business, external factors such as insufficient downstream financing have impacted customer order prices, which remain at low levels compared to previous years [1] - The CDMO business has seen some improvement in gross margins, but high fixed operational costs related to depreciation, energy consumption, and daily maintenance have resulted in significant losses [1] Group 3: Impairment Provisions - Due to the ongoing losses in the cell and gene therapy CDMO business, the company has conducted preliminary impairment tests in accordance with accounting standards [1] - The company has made provisions for impairment related to inventory, long-term assets, and contract orders, which have negatively impacted the current net profit [1]